Using the integration of several biophysical techniques, including crystallography, isothermal titration calorimetry (ITC), differential scanning fluorimetry (DSF) and nuclear magnetic resonance (NMR) in combination with computational techniques and organic chemistry, we expect to evolve series of compounds with high affinity and selectivity based on previously identified and characterized molecules (fragments) that target the enzyme Dihydrofolate Reductase from Mycobacterium tuberculosis and other pathogenic microorganisms including Staphylococcus aureus and Candida Albicans. We also expect that these molecules have a poor effect on the human enzymes involved in folate metabolism. This project involves an intensive collaboration with Prof. Chris Abell group from the University of Cambridge which gives strong support on organic chemistry synthesis strategies. The selected student will have the opportunity to participate in a multidisciplinary team using a multi-approach strategy for drug discovery, which includes techniques of molecular biology, biochemistry, physical techniques and organic chemistry. This will put the selected student in contact with the advanced techniques used in both industry and academia involved in the development of new drugs.
How to apply: Please direct informal enquiries and requests for further information to Dr Marcio V B Dias ([email protected]
Details on the formal application procedure can be found at http://www.go.warwick.ac.uk/pgapply
This funded studentship is open to UK/EU nationals*, covers all tuition fees and provides an annual tax-free stipend of ca. £14,800 for 3.5 years. Applicants should have an honours degree (at least II.1 or equivalent) in chemistry, or other relevant disciplines. It is highly desirable that the applicants have at least experience in one of the following discipline: protein production and analysis, structural biology and biophysics, protein-ligand docking or organic chemistry. *For full eligibility criteria for this post please see: View Website
Dias, MV, Tyrakis, P, Domingues, RR, Paes Leme, AF, Blundell TL. Mycobacterium tuberculosis dihydrofolate reductase reveals two conformational states a possible low affinity mechanism to antifolate drugs. Structure, 22(1), 94-103, 2014. Doi: 10.1016/j.str.2013.09.022.
Dias, MV, Santos, JC, Libreros-Zúñiga, GA, Ribeiro, JA, Chavez-Pacheco, SM. Folate biosynthesis pathway: mechanisms and insights into drug design for infectious diseases. Future Med Chem, 10(8), 935-959, 2018. Doi: 10.4155/fmc-2017-0168.
Kavanagh, ME, Coyne, AG, McLean, KJ, Games, GG, Levy, CW, Marino, LB, de Carvalho, LP, Chan, DS, Hudson, SA, Surade, S, Leys, D. Munro, AW, Abell, C. Fragment-based approaches to the development of Mycobacterium tuberculosis CYP121 inhibitors. J Med Chem, 59(7), 3272-3302, 2016. Doi: 10.1021/acs.jmedchem.6b00007.